Erivedge
 |
|
|---|---|
 |
|
| Systematic (IUPAC) name | |
| 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide | |
| Clinical data | |
| Trade names | Erivedge |
| Licence data | US FDA:link |
| Pregnancy cat. | D (US) |
| Legal status | -only (US) |
| Routes | Oral |
| Identifiers | |
| ATC code | L01XX43 |
| PubChem | CID 24776445 |
| UNII | 25X868M3DS |
| ChEBI | CHEBI:66903  |
| Synonyms | GDC-0449, RG-3616 |
| Chemical data | |
| Formula | C19H14Cl2N2O3S |
| Mol. mass | 421.30 g/mol |
|
SMILES
|
|
|
InChI
|
|
Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC). The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval.[1] The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma as of June 2011[update].[2] The drug was developed by the biotechnology / pharmaceutical company Genentech, which is headquartered at South San Francisco, California, USA.
Contents
|
Indication
Vismodegib is indicated for patients with basal cell carcinoma (BCC), which has metastasized to other parts of the body, relapsed after surgery, or cannot be treated with surgery or radiation.[3]
Mechanism of action
The substance acts as a cyclopamine-competitive antagonist of the smoothened receptor (SMO) which is part of the hedgehog signaling pathway.[2] SMO inhibition causes the transcription factors GLI1 and GLI2 to remain inactive, which prevents the expression of tumor mediating genes within the hedgehog pathway.[4] This pathway is pathogenetically relevant in more than 90% of basal-cell carcinomas.[5]
See also
- Cyclopamine, a naturally occurring SMO antagonist
References
- ^ "Vismodegib, First Hedgehog Inhibitor, Approved for BCC Patients".
- ^ a b Molecule of the Month. June 2011.
- ^ "FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma".
- ^ "Vismodegib (GDC-0449) Smoothened Inhibitor - BioOncology".
- ^ H. Spreitzer (4 July 2011). "Neue Wirkstoffe - Vismodegib". sterreichische Apothekerzeitung (in German) (14/2011): 10.
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Most Recent Erivedge Forums: 
My son has been taking Erivedge for 4 months. His facial hair, eyebrows re thinning. His hairline is receeding. I have heard some people take this medicine for 6 months and off 6 months. I am afraid if he stays on it full time -- he will loose all of his body hair and I am afraid of what this will do him. I have heard people on Chemotherapy take 5,000mcg Biotin. Has anyone tried this to help counteract the affects of hair loss. Would taking this medicine for 3 months on and 3 months off help to couteract the affects of hair loss while keeping the cancer at bay?
Monday, 2/4/2013 10:44:09 AM 5 Replies Subscribe to thread 237396
I am starting a 10 month program for BCC, and I have a physically demanding job, with a lot of traveling involved. Will I still be able to work and travel while taking this medication?
Thursday, 1/17/2013 1:52:55 PM 3 Replies Subscribe to thread 233112
All text is available under the terms of the GFDL (GNU Free Documentation License)
http://en.wikipedia.org/wiki/Vismodegib
